Novel injectable fluorinated contrast agents with enhanced radiopacity

Artif Cells Blood Substit Immobil Biotechnol. 1994;22(4):1421-8. doi: 10.3109/10731199409138846.

Abstract

Novel emulsions containing iodinated fluorinated radiopaque (IFR) molecules were prepared and evaluated as injectable contrast agents with prolonged intravascular persistence. Various stable IFR/egg yolk phospholipid emulsions were produced, heat-sterilized, and tested as to their radiopacity, shelf-stability and in vivo tolerance. No significant change in mean particle sizes was observed over a 3-month storage period at 40 degrees C. Intravenous injection of an emulsion of a 0.39 g/kg bw dose of a typical IFR, C6F13CH = CIC6H13 (F6H6IE) in rabbits led to high contrast in the liver and spleen. The same radiopacity of the liver was achieved with 7 times less IFR than perfluorooctyl bromide. Histological examination after 24 h, and blood analysis after 24, 48 h and 7 days, demonstrated normal functioning of the liver, even when high concentrations of IFR were present. The neat IFR was tolerated i.p. in mice at a 45 g/kg bw dose. Emulsified IFR was tolerated in rats and mice i.v. at a 8 g/kg bw dose. The iodinated fluorinated molecule tested appears promising for the formulation of new contrast agents for diagnosis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Contrast Media / administration & dosage*
  • Contrast Media / pharmacokinetics
  • Emulsions
  • Half-Life
  • Hydrocarbons, Fluorinated / administration & dosage*
  • Hydrocarbons, Fluorinated / pharmacokinetics
  • Injections, Intravenous
  • Male
  • Rabbits
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Contrast Media
  • Emulsions
  • Hydrocarbons, Fluorinated
  • 1,1,1,2,2,3,3,4,4,5,5,6,6---tridecafluoro-8-iodo-7-tetradecene